Compare PGEN & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | IRMD |
|---|---|---|
| Founded | 1998 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2014 |
| Metric | PGEN | IRMD |
|---|---|---|
| Price | $4.76 | $97.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.67 | ★ $72.00 |
| AVG Volume (30 Days) | ★ 3.8M | 75.0K |
| Earning Date | 03-18-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 0.69% |
| EPS Growth | N/A | ★ 13.00 |
| EPS | N/A | ★ 1.65 |
| Revenue | $6,309,000.00 | ★ $80,511,268.00 |
| Revenue This Year | $342.78 | $15.17 |
| Revenue Next Year | $478.46 | $10.15 |
| P/E Ratio | ★ N/A | $60.01 |
| Revenue Growth | ★ 59.20 | 12.91 |
| 52 Week Low | $1.11 | $47.48 |
| 52 Week High | $5.23 | $104.93 |
| Indicator | PGEN | IRMD |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 46.60 |
| Support Level | $4.37 | $96.46 |
| Resistance Level | $4.88 | $100.44 |
| Average True Range (ATR) | 0.40 | 2.92 |
| MACD | 0.01 | -0.70 |
| Stochastic Oscillator | 71.03 | 17.09 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.